ASCO-GI 2019—ICI and SBRT combination safe, feasible in aPDAC


  • Melissa Pandika
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Immune checkpoint inhibition (ICI) combined with stereotactic body radiation therapy (SBRT) was safe and well-tolerated in advanced pancreatic adenocarcinoma (aPDAC).

Why this matters

  • Chemotherapy only modestly improves aPDAC outcome.
  • Single-agent ICI has limited effectiveness in PDAC, possibly due to an immunosuppressive tumor microenvironment.
  • Since SBRT boosts antitumor immunity, it may enhance ICI activity, suggesting that combining the 2 therapies may offer more clinical benefit for aPDAC than either alone.

Study design

  • 51 patients who had received prior chemotherapy for aPDAC underwent 1 of 4 treatment regimens until unacceptable toxicity or disease progression:
    • Durvalumab 1500 mg every 4 weeks + SBRT 1 fraction x 8 Gy on day 1.
    • SBRT 5 fractions x 5 Gy, followed by durvalumab.
    • Durvalumab + Tremelimumab 75 mg every 4 weeks + SBRT 1 fraction x 8 Gy on day 1.
    • SBRT 5 fractions x 5 Gy, followed by durvalumab + tremelimumab.
  • Primary objectives were safety and feasibility.

Key results                          

  • 31 patients were evaluable.
  • Median PFS was 2.2 months.
  • Median OS was 4.9 months.
  • 2 patients who received 5 Gy x 5 + durvalumab +tremelimumab had partial responses with a duration longer than 12 months.  

Limitations

  • Small pilot study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit